Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Επικοινωνία Submitted by Δημήτρης Σπάχος on Δευ, 05/04/2015 - 10:46
